Provided by Tiger Fintech (Singapore) Pte. Ltd.

Day One Biopharmaceuticals Inc.

6.67
-0.0200-0.30%
Post-market: 6.53-0.1409-2.11%19:24 EDT
Volume:1.16M
Turnover:7.70M
Market Cap:676.09M
PE:-9.39
High:6.75
Open:6.57
Low:6.53
Close:6.69
Loading ...

Day One Biopharm Is Maintained at Buy by Goldman Sachs

Dow Jones
·
25 Mar

Buy Rating for Day One Biopharmaceuticals: Strong Financial Position and Strategic Growth Potential

TIPRANKS
·
11 Mar

High Growth Tech Stocks In The US With Promising Potential

Simply Wall St.
·
11 Mar

Day One Biopharm Is Maintained at Overweight by JP Morgan

Dow Jones
·
05 Mar

Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory

Insider Monkey
·
05 Mar

Day One Biopharma’s Earnings Call Highlights Growth and Challenges

TIPRANKS
·
28 Feb

Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations

Zacks
·
26 Feb

Promising Growth Potential for Day One Biopharmaceuticals Driven by Ojemda and FIREFLY-2 Trial

TIPRANKS
·
26 Feb

Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
26 Feb

Day One Biopharm Price Target Maintained With a $32.00/Share by Needham

Dow Jones
·
26 Feb

Oppenheimer Sticks to Their Hold Rating for Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
26 Feb

Day One Biopharmaceuticals Reports Strong 2024 Results

TIPRANKS
·
26 Feb

Promising Growth and Strategic Positioning Justify Buy Rating for Day One Biopharmaceuticals

TIPRANKS
·
26 Feb

Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
26 Feb

Day One Biopharmaceuticals Reports 2024 Financial Results

TIPRANKS
·
26 Feb

Day One Biopharmaceutical Q4 GAAP EPS $(0.69) Misses $(0.36) Estimate, Sales $29.21M Beat $27.79M Estimate

Benzinga
·
26 Feb

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

GlobeNewswire
·
26 Feb

Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates

Zacks
·
21 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
21 Feb

Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect?

Zacks
·
13 Feb